Vascular events in patients with head and neck cancer: A systematic review and meta‐analysis

Abstract

ObjectiveTo assess the incidence of vascular events in patients with head and neck cancer.Review MethodsPrimary studies identified through April 2023. Meta‐analysis was performed.ResultsThere were 146 studies included in the systematic review. Rates of events were collected in the overall group, those with chemoprophylaxis, and those that underwent surgery, radiation, or chemotherapy. Of 1 184 160 patients, 4.3% had a vascular event. Radiation therapy had highest risk of overall events and stroke when compared to surgery and chemotherapy. Chemotherapy had a higher risk of stroke and overall events when compared to surgery.ConclusionsVascular events occur in 4%–5% of patients with head and neck cancer. Our data does not support the use of routine anticoagulation. Patients undergoing radiation therapy had the highest frequency of events.

Immune checkpoint inhibitors-associated thrombosis in patients with head and neck cancer: a study of the Spanish society of medical oncology (SEOM) thrombosis and cancer group

“…However, a literature search reveals a review article published by Haen et al [5], concluding that HNCs have biological/molecular characteristics associated with a high risk of VTE/AT, albeit with a low incidence rate. In fact, Monaghan et al [6] reported a vascular event incidence of 4-5%.…”

“…The meta-analysis by Monaghan et al [6] describes that patients receiving radiotherapy have a higher frequency of vascular events compared to surgery and chemotherapy. Indeed, a recent study [7] concerning surgical procedures reported an incidence rate of 1.3%.…”